Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

Pearlman BL; Ehleben C

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

【24h】

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

机译：聚乙二醇干扰素α-2b和利巴韦林在C型肝炎病毒基因型1和慢病毒学应答患者中进行48或72周的随机试验。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

We read with great interest the article by Buti et al. about the optimum duration of treatment for genotype 1-infected slow res-ponders in the SUCCESS trial; however, we disagree with the authors' conclusion that 48 weeks of therapy with peginterferon and ribavirin, instead of 72 weeks, should remain the standard of care.

机译：我们非常感兴趣地阅读了Buti等人的文章。关于成功试验中基因型1感染的慢反应者的最佳治疗时间;但是，我们不同意作者的结论，即聚乙二醇干扰素和利巴韦林治疗的48周而不是72周应该是标准的治疗方法。

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2010年第4期|共3页
作者
Pearlman BL; Ehleben C;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response. [J] . Pearlman BL, Ehleben C Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2010,第4期

机译：聚乙二醇干扰素α-2b和利巴韦林在C型肝炎病毒基因型1和慢病毒学应答患者中进行48或72周的随机试验。
2. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. [J] . Ferenci P, Laferl H, Scherzer TM, Gastroenterology . 2010,第2期

机译：丙型肝炎基因型1和4的病毒学应答较慢的患者，聚乙二醇干扰素α-2a/利巴韦林治疗48或72周。
3. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. [J] . Akuta N, Suzuki F, Hirakawa M, Journal of Medical Virology . 2009,第3期

机译：在日本对感染HCV基因型1b的患者进行的聚乙二醇干扰素联合利巴韦林联合治疗48和72周的病例对照研究：HCV核心区域的氨基酸取代可作为持续病毒学应答的预测指标。
4. Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial [C] . M. Rodriguez Torres, F.J. Torriani, E. Lissen International AIDS Conference . 2004

机译：HCV / HIV与Peginterferon Alfa-2a（40KD）（Pegasys〜R）加上利韦韦林（Copegus〜R）在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应（SVR）的可预测性
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial [O] . Qingxian Cai, Xiaohong Zhang, Chaoshuang Lin, -1

机译：丙型肝炎病毒基因型6慢性感染患者具有快速病毒学应答的聚乙二醇干扰素联合利巴韦林治疗24到48周：一项非劣效性随机对照试验
7. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. [O] . Buti, Maria, Lurie, Yoav, Zakharova, Natalia G, 2010

机译：聚乙二醇干扰素α-2b和利巴韦林在丙型肝炎病毒基因型1和慢病毒学应答患者中进行48或72周的随机试验。

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

摘要

著录项

相似文献

相关主题

期刊订阅